The dual antagonist to both ETAR and ETBR, Macitentan, has been approved for clinical management of pulmonary arterial hypertension (PAH) [16]; the secondary effect of the drug on vertebral bone mass is of great interest but still not reported. The gene discussed is EDNRA; the disease is pulmonary arterial hypertension.